Cannabis and Menopause Symptoms
What the evidence actually says about using cannabis for hot flashes, sleep, mood, joint pain, and genitourinary symptoms during menopause.
A lot of women are using cannabis for menopause symptoms — surveys suggest more than for any other medical reason in midlife. The marketing is way ahead of the science. There are zero high-quality randomized trials of cannabis specifically for menopause symptoms. What we have is survey data, mechanistic plausibility, and extrapolation from sleep and pain research in other populations. That doesn't mean it doesn't work. It means we don't actually know, and anyone telling you otherwise — including dispensary staff and wellness influencers — is guessing.
Not Medical Advice
This article is not medical advice. It summarizes published evidence as of 2024. Menopause symptoms overlap with conditions that require evaluation — thyroid disease, depression, sleep apnea, cardiovascular risk changes. Talk to a clinician familiar with both menopause and cannabis before substituting cannabis for evidence-based treatments like menopausal hormone therapy (MHT). Cannabis interacts with several common medications, including some antidepressants and blood thinners.
Plain-Language Summary
Menopause is the point 12 months after a person's last menstrual period; perimenopause is the transition leading up to it, often lasting several years. Common symptoms include hot flashes, night sweats, sleep disruption, mood changes, joint pain, brain fog, and genitourinary changes (vaginal dryness, painful sex, urinary symptoms).
Surveys in North America show a sizeable minority of midlife women use cannabis to manage these symptoms. A 2020 survey of women veterans found roughly 27% of cannabis users reported using it for menopause symptoms [1]. A 2022 Alberta study reported similar self-medication patterns [2]. Use is common. Evidence is not.
There are no randomized controlled trials of cannabis for menopause symptoms as a primary indication. Everything below is extrapolated.
What Probably Works
Honestly: nothing in cannabis has reached "probably works" status for menopause symptoms specifically. No data
If we widen the lens to symptoms that overlap with menopause (chronic pain, generalized anxiety, sleep-onset insomnia in non-menopausal adults), there is moderate evidence that cannabis or specific cannabinoids can help — but these populations are not menopausal women, and effect sizes are modest [3][4]. Treating that as proof for menopause is a leap.
The most defensible statement: if you already have chronic pain or anxiety that happens to coexist with menopause, the general cannabis-and-pain literature applies. That is not the same as cannabis treating menopause.
What Might Work (Weak Evidence)
Sleep. Menopausal sleep disruption is driven by vasomotor symptoms, mood, and circadian shifts. Small trials of cannabinoids (mostly nabilone and CBD) in other populations show modest improvements in sleep onset and subjective sleep quality Weak / limited [4]. Whether this translates to menopausal sleep specifically is unstudied. Tolerance to THC's sedative effect can develop within weeks [5].
Anxiety and mood. CBD has shown anxiolytic effects in induced-anxiety paradigms and small trials in social anxiety disorder Weak / limited [6]. Perimenopausal mood symptoms have distinct hormonal drivers, and no trial has tested CBD in this population.
Joint and muscle pain. Midlife joint pain is common and underrecognized. Cannabis shows weak-to-moderate effects in chronic non-cancer pain Weak / limited [3]. Topical CBD for joint pain is widely marketed but has minimal controlled evidence.
Endocannabinoid system involvement. Estrogen modulates endocannabinoid tone, and CB1 receptors are expressed in tissues relevant to menopause Weak / limited [7]. This is mechanistic plausibility, not clinical proof.
What Doesn't Work or Has Weak Evidence
Hot flashes and night sweats. There is no good evidence cannabis reduces vasomotor symptoms. No data THC can actually cause vasodilation and flushing, which some users describe as worsening hot flashes. Survey data showing women "feel" cannabis helps hot flashes is uncontrolled and confounded by sedation and mood effects.
Vaginal dryness and painful sex. Cannabis-infused suppositories and lubricants are sold for this purpose. There are no controlled trials. No data Vaginal estrogen has strong evidence and minimal systemic absorption [8] — it is the standard of care for genitourinary syndrome of menopause.
Bone loss prevention. Animal studies suggest CB2 receptor activity affects bone remodeling Weak / limited. No human data supports cannabis for osteoporosis prevention. Heavy chronic cannabis use has been associated with lower bone density in some studies [9].
"Indica vs. sativa" for menopause. Dispensary advice that indica strains help sleep and sativa strains help mood is folklore, not pharmacology. Chemovar (the actual cannabinoid and terpene profile) matters more than the indica/sativa label Disputed [10].
What We Don't Know
Almost everything specific to menopause:
- Whether any cannabinoid reduces hot flash frequency or severity
- Dose-response for any menopause symptom
- Whether CBD-dominant, THC-dominant, or balanced products work differently
- Long-term safety in postmenopausal women, who face rising cardiovascular and bone risks
- Interactions with menopausal hormone therapy
- Whether topical/vaginal cannabis products are absorbed, safe, or effective
- Effects on cognition in a population already concerned about "brain fog"
A few observational studies and one or two pilot trials are in progress, but as of 2024 the evidence base is genuinely thin.
Comparison With Standard Treatments
Menopausal hormone therapy (MHT/HRT) has the strongest evidence for vasomotor symptoms, genitourinary symptoms, and bone protection in appropriately selected patients Strong evidence [8][11]. The North American Menopause Society's 2022 position statement supports MHT for symptomatic women under 60 or within 10 years of menopause, with risk stratification [11].
Non-hormonal prescription options with RCT support include SSRIs/SNRIs (paroxetine is FDA-approved for hot flashes), gabapentin, oxybutynin, and fezolinetant (a neurokinin-3 antagonist approved in 2023) Strong evidence.
Cognitive behavioral therapy has good evidence for menopause-related insomnia and the distress associated with hot flashes Strong evidence.
Cannabis is not a replacement for any of these. It may be a reasonable adjunct for some symptoms in some patients, particularly when standard therapies are contraindicated or not tolerated — but that is a clinical judgment call, not an evidence-based recommendation.
Risks and Practical Considerations
- Cardiovascular. Cannabis acutely raises heart rate and can transiently raise blood pressure. Cardiovascular risk rises after menopause; this matters [12].
- Cognition. THC impairs short-term memory and executive function acutely. In a population already noticing cognitive changes, this can be distressing or mistaken for worsening menopause symptoms.
- Falls. Sedation plus age-related balance changes raises fall risk.
- Drug interactions. CBD inhibits CYP2C9, CYP2C19, and CYP3A4. Relevant interactions include warfarin, some SSRIs, tamoxifen, and statins [13].
- Dependence. Cannabis use disorder occurs in roughly 9% of users overall, higher with daily use [14].
- Pulmonary. Smoked and vaporized cannabis affect lung tissue; midlife is a sensible time to avoid inhaled products.
- Product quality. Unregulated CBD products frequently mislabel cannabinoid content [15]. If you use cannabis, prefer regulated markets and request a certificate of analysis.
Bottom Line
Cannabis use for menopause is common, plausible for some symptoms, and almost entirely unstudied as a primary treatment. If standard options (MHT, non-hormonal prescriptions, CBT, vaginal estrogen) are available and appropriate, those have real evidence behind them. Cannabis may help with sleep, anxiety, or pain that happens to coexist with menopause — but treating it as a menopause therapy specifically is, right now, an extrapolation. The honest answer is: we need the trials, and they haven't been done.
Sources
- Peer-reviewed Han L, et al. (2023). Cannabis use for menopause symptom management among midlife women veterans. Menopause, 30(4): 387-394.
- Peer-reviewed Slavin MN, et al. (2023). Cannabis use patterns among midlife women: an Alberta-based survey. Menopause, 30(10).
- Peer-reviewed National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. ↗
- Peer-reviewed Suraev AS, et al. (2020). Cannabinoid therapies in the management of sleep disorders: a systematic review. Sleep Medicine Reviews, 53: 101339.
- Peer-reviewed Babson KA, Sottile J, Morabito D. (2017). Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports, 19(4): 23.
- Peer-reviewed Bergamaschi MM, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6): 1219-1226.
- Peer-reviewed Gorzalka BB, Dang SS. (2012). Minireview: Endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology, 153(3): 1016-1024.
- Peer-reviewed The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 29(7): 767-794.
- Peer-reviewed Sophocleous A, et al. (2017). Heavy Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of Fractures. American Journal of Medicine, 130(2): 214-221.
- Peer-reviewed Piomelli D, Russo EB. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1): 44-46.
- Government NICE Guideline NG23. (Updated 2019). Menopause: diagnosis and management. National Institute for Health and Care Excellence (UK). ↗
- Peer-reviewed Page RL, et al. (2020). Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation, 142(10): e131-e152.
- Peer-reviewed Brown JD, Winterstein AG. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8(7): 989.
- Peer-reviewed Hasin DS, et al. (2015). Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12): 1235-1242.
- Peer-reviewed Bonn-Miller MO, et al. (2017). Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA, 318(17): 1708-1709.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...